Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310205 · ClinicalTrials.gov registry record
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
A clinical trial of Chronic Hepatitis C, sponsored by SciClone Pharmaceuticals.
- Completed
- Registry status
- 12
- Enrollment target
- 4
- Study locations
NCT01310205 is a study of Chronic Hepatitis C that has completed, run by SciClone Pharmaceuticals. The registered enrollment target is 12 participants, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01310205, a study of Chronic Hepatitis C, has completed, sponsored by SciClone Pharmaceuticals.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV.
Conditions Studied
Interventions
- DRUG SCV-07
Study Locations (4)
California
- AGMG Clinical Research - Anaheim
Kentucky
- Univ of Louisville Med/Dental Complex - Louisville
Ohio
- University of Cincinnati Medical Center - Cincinnati
Washington
- Walter Reed Army Medical Center - Washington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01310205
The ClinicalTrials.gov registry entry for NCT01310205 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (94% lower). The listed sponsor is SciClone Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which SCV-07 is the first listed.
NCT01310205 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Kentucky, Ohio.
Frequently Asked Questions
What is clinical trial NCT01310205 about?
NCT01310205 is a clinical study titled "Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV". This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV.
What is the current status of trial NCT01310205?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2010-08. Estimated completion is 2012-03.
What conditions does trial NCT01310205 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT01310205?
The interventions under investigation include: SCV-07 (DRUG).
Who is sponsoring clinical trial NCT01310205?
This trial is sponsored by SciClone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01310205 being conducted?
This trial has 4 study locations across California, Kentucky, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
COMPLETED · Phase 1
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
COMPLETED · Phase 3
-
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
COMPLETED · Phase 3
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
COMPLETED · Phase 2
-
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.